Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (Cynomolgus Monkeys)
Guo, Linlin, Overholser, Jay, Good, Anthony J, Ede, Nicholas J, Kaumaya, Pravin T P
Published in Frontiers in oncology (13.05.2022)
Published in Frontiers in oncology (13.05.2022)
Get full text
Journal Article
Clinical and Immunologic Responses to a B-Cell Epitope Vaccine in Patients with HER2/neu-Overexpressing Advanced Gastric Cancer-Results from Phase Ib Trial IMU.ACS.001
Wiedermann, Ursula, Garner-Spitzer, Erika, Chao, Yee, Maglakelidze, Marina, Bulat, Iurie, Dechaphunkul, Arunee, Arpornwirat, Wichit, Charoentum, Chaiyut, Yen, Chia-Jui, Yau, Thomas Cheung, Tanasanvimon, Suebpong, Maneechavakajorn, Jedzada, Sookprasert, Aumkhae, Bai, Li-Yuan, Chou, Wen-Chi, Ungtrakul, Teerapat, Drinic, Mirjana, Tobias, Joshua, Zielinski, Christoph C, Chong, Leslie, Ede, Nicholas J, Marino, Mark T, Good, Anthony J
Published in Clinical cancer research (01.07.2021)
Published in Clinical cancer research (01.07.2021)
Get full text
Journal Article
nextHERIZON: A phase 2 study of HER-Vaxx, a HER2-targeting peptide vaccine, in combination with chemotherapy or pembrolizumab in patients with HER2 metastatic or advanced gastric/gastroesophageal adenocarcinoma that progressed on or after trastuzumab treatment
Price, Timothy Jay, Chong, Leslie Mi Ok, Ede, Nicholas, Nixon, Bonnie, Withana, Nimali, Yavrom, Sharon, Selvaggi, Giovanni, Good, Anthony J.
Published in Journal of clinical oncology (01.02.2023)
Published in Journal of clinical oncology (01.02.2023)
Get full text
Journal Article
HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2-overexpressing metastatic or advanced gastric/GEJ adenocarcinoma— Overall survival analysis
Maglakelidze, Marina, Ryspayeva, Dinara E., Andric, Zoran, Petrovic, Zoran, Bulat, Iurie, Nikolic, Ivan, Nagarkar, Rajnish, Wiedermann, Ursula, Blumenstein, Brent A., Chong, Leslie Mi Ok, Ede, Nicholas, Nixon, Bonnie, Yavrom, Sharon, Selvaggi, Giovanni, Good, Anthony J., Chawla, Tanuj
Published in Journal of clinical oncology (01.02.2023)
Published in Journal of clinical oncology (01.02.2023)
Get full text
Journal Article
IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of imu-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101)
Richardson, Gary Edward, Park, John J., Boyer, Michael J., Gutierrez, Martin, Carbone, David Paul, Savvides, Panayiotis, Kaumaya, Pravin, Bekaii-Saab, Tanios S., Phan, Tri Guang, Chong, Leslie Mi Ok, Cha, Steven, Ede, Nicholas, Nixon, Bonnie, Good, Anthony J
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Laeufle, Rita, Maglakelidze, Marina, Bulat, Iurie, Ryspayeva, Dinara, Zoran, Andric, Chawla, Tanuj, Nikolic, Ivan, Nagarkar, Rajnish, Venkata, Giri, Choudhary, Vaibhav, Radosavljevic, Davorin, Singh, Rajesh Kumar, Wiedermann, Ursula, Good, Anthony J, Ede, Nick, Chong, Leslie Mi Ok
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Chao, Yee, Yau, Thomas, Maglakelidze, Marina, Bulat, Iurie, Tanasanvimon, Suebpong, Charoentum, Chaiyut, Arpornwirat, Wichit, Maneechavakajorn, Jedzada, Dechaphunkul, Arunee, Ungtrakul, Teerapat, Yen, Chia-Jui, Bai, Li-Yuan, Chou, Wen-Chi, Wiedermann, Ursula, Good, Anthony J, Ede, Nick, Chong, Leslie Mi Ok
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Abstract CT059: A Phase Ib open label multicenter study with a HER2/neu peptide vaccine administered with cisplatin and 5-fluorouracil or capecitabine chemotherapy shows safety, immunogenicity and clinical response in patients with HER2/Neu overexpressing advanced cancer of the stomach
Wiedermann, Ursula, Garner-Spitzer, Erika, Chao, Yee, Bulat, Iurie, Dechaphunkul, Arunee, Arpornwirat, Wichit, Charoentum, Chaiyut, Yen, Chia-Jui, Yau, Thomas Cheung, Maglakelidze, Marina, Tanasanvimon, Suebpong, Maneechavakajorn, Jedzada, Sookprasert, Aumkhae, Bai, Li-Yuan, Chou, Wen-Chi, Ungtrakul, Teerapat, Zielinski, Christoph C., Chong, Leslie, Ede, Nick, Good, Anthony J
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Published in Cancer research (Chicago, Ill.) (01.07.2019)
Get full text
Journal Article
A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction
Wiedermann, Ursula, Good, Anthony J, Garner-Spitzer, Erika, Chao, Yee, Bulat, Iurie, Dechaphunkul, Arunee, Arpornwirat, Wichit, Charoentum, Chaiyut, Yen, Chia-Jui, Yau, Thomas Cheung, Maglakelidze, Marina, Tanasanvimon, Suebpong, Maneechavakajorn, Jedzada, Sookprasert, Aumkhae, Bai, Li-Yuan, Chou, Wen-Chi, Ungtrakul, Teerapat, Chong, Leslie, Ede, Nick
Published in Journal of clinical oncology (01.02.2019)
Published in Journal of clinical oncology (01.02.2019)
Get full text
Journal Article